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Abstract
Background: GPCRs regulate a remarkable diversity of biological functions, and are thus often targeted for drug therapies.
Stimulation of a GPCR by an extracellular ligand triggers receptor signaling via G proteins, and this process is highly
regulated. Receptor activation is typically accompanied by desensitization of receptor signaling, a complex feedback
regulatory process of which receptor internalization is postulated as a key event. The in vivo significance of GPCR
internalization is poorly understood. In fact, the majority of studies have been performed in transfected cell systems, which
do not adequately model physiological environments and the complexity of integrated responses observed in the whole
animal.
Methods and Findings: In this study, we used knock-in mice expressing functional fluorescent delta opioid receptors (DOR-
eGFP) in place of the native receptor to correlate receptor localization in neurons with behavioral responses. We analyzed
the pain-relieving effects of two delta receptor agonists with similar signaling potencies and efficacies, but distinct
internalizing properties. An initial treatment with the high (SNC80) or low (AR-M100390) internalizing agonist equally
reduced CFA-induced inflammatory pain. However, subsequent drug treatment produced highly distinct responses. Animals
initially treated with SNC80 showed no analgesic response to a second dose of either delta receptor agonist. Concomitant
receptor internalization and G-protein uncoupling were observed throughout the nervous system. This loss of function was
temporary, since full DOR-eGFP receptor responses were restored 24 hours after SNC80 administration. In contrast,
treatment with AR-M100390 resulted in retained analgesic response to a subsequent agonist injection, and ex vivo analysis
showed that DOR-eGFP receptor remained G protein-coupled on the cell surface. Finally SNC80 but not AR-M100390
produced DOR-eGFP phosphorylation, suggesting that the two agonists produce distinct active receptor conformations
in vivo which likely lead to differential receptor trafficking.
Conclusions: Together our data show that delta agonists retain full analgesic efficacy when receptors remain on the cell
surface. In contrast, delta agonist-induced analgesia is abolished following receptor internalization, and complete behavioral
desensitization is observed. Overall these results establish that, in the context of pain control, receptor localization fully
controls receptor function in vivo. This finding has both fundamental and therapeutic implications for slow-recycling GPCRs.
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Introduction
G protein coupled receptors (GPCRs) form the largest family of
membrane receptors [1]. A variety of physiological functions are
regulated by GPCRs, which represent the most common target for
therapeutic drugs. Stimulation of a GPCR by an extracellular
messenger, either physiological or synthetic, triggers intracellular
receptor signaling via heterotrimeric G proteins. This process is
highlyregulated andreceptoractivationis typicallyaccompaniedby
desensitization of receptor signaling, a complex feedback regulatory
process whereby receptor responsiveness decreases upon continued
agonist stimulation. Receptor trafficking is considered to be a key
process in the regulation of receptor signaling. In particular, many
studies have shown that receptor stimulation by an agonist
concomitantly leads to receptor signaling and redistribution of
receptor molecules away from the cell surface (for review see [2–3]).
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5425The significance of receptor endocytosis in the regulation of
GPCR function is under intense investigation, and many aspects
deserve further clarification. First, receptor internalization may
influence agonist efficacy in different ways. The most straightfor-
ward hypothesis proposes that receptor internalization reduces
agonist effects, as fewer receptors are available at the cell surface.
On the contrary, it has also been suggested that receptor
endocytosis promotes rapid resensitization by recycling the
receptor back to the cell surface, which contributes to the main-
tenance of a large population of active receptors at the plasma
membrane [4]. Second, receptor internalization may not simply
terminate intracellular signaling. Classically, agonist binding
results in phosphorylation of the GPCR, which in turn leads to
recruitment of b-arrestins. Binding to these adaptor proteins
initiates receptor internalization and physically prevents further
receptor interaction with heterotrimeric G proteins. However,
recent findings suggest that the internalized receptor-b-arrestin
complex can in turn recruit signaling proteins and initiate further
intracellular signaling [1,5,6]. Third, the physiological relevance of
many receptor trafficking studies is limited, as the majority have
been performed in transfected cellular models. These in vitro
systems may not reflect in vivo situations in terms of receptor
density, protein content of receptor-expressing cells, or even
receptor localization within subcellular compartments, as is the
case for neurons [3]. Additionally, data from cellular models
provide no understanding of how receptor trafficking influences
integrated responses in the living organism. Fourth, individual
GPCRs vastly differ in their trafficking properties, leading to
specific regulatory mechanisms for each receptor. Overall, the
characterization of receptor trafficking in native tissues is only
beginning [7].
Due to limited availability of specific antibodies, in vivo
trafficking of GPCRs has been investigated for only a limited
number of native receptors [8–12]. Recently we have created
knock-in mice expressing a fully functional fluorescent delta opioid
receptor (DOR-eGFP) in place of the endogenous delta receptor.
In these animals DOR-eGFP are expressed at physiological levels
within their native environment. Furthermore, these receptors are
directly visible in vivo. These mutant mice have proven to be an
exceptional tool in studying receptor neuroanatomy, real-time
receptor trafficking in live neurons, and receptor movements in vivo
[13]. This unique animal model can now be used to determine the
relationship between receptor trafficking in neurons and receptor
function at a behavioral level. Our previous work using DOR-
eGFP mice showed that treatment with the delta agonist SNC80
triggered massive receptor endocytosis throughout the nervous
system, together with locomotor activation. We further showed
that mice with internalized receptors did not show locomotor
activation following a second drug administration [13]. This was a
first indication that internalization may impact delta receptor
function in vivo, at least in the case of locomotor responses.
The opioid system is involved in pain control, reward
processing, and stress responses. Genetic approaches have
revealed that the delta receptor fulfills roles highly distinct from
those of mu and kappa opioid receptors [14,15]. Several studies
have shown that delta receptors can specifically alleviate persistent
pain [16–20]. In the present study we examine the regulation of
delta opioid receptor function in the control of inflammatory pain.
We first characterize trafficking properties of two delta receptor
agonists in live neurons from DOR-eGFP mice. We show that the
two compounds have very distinct internalizing properties, despite
similar in vitro signaling potencies and efficacies. Further, we find
in vivo that a first injection of each agonist in DOR-eGFP mice
reduces inflammatory pain, with similar efficacy for the two drugs.
Importantly, we find that a subsequent agonist administration in
vivo has very distinct consequences on the behavioral response.
The high-internalizing agonist no longer relieves pain, indicating
that acute in vivo desensitization has occurred. In contrast the low-
internalizing agonist remains fully active following the second
administration, demonstrating that non-internalized receptors
remain functional. Finally, we show that receptor phosphorylation
and uncoupling parallels receptor internalization, and that
restoration of surface receptors reinstate opioid analgesia. These
data unambiguously demonstrate that receptor internalization
fully determines drug efficacy in vivo.
Results
SNC80 and ARM390 show similar pharmacology at the
DOR-eGFP receptor
SNC80 [21] is a widely used non-peptidic compound that shows
high delta selectivity in vivo, and was chosen as a reference delta
receptor agonist in this study. AR-M100390 (ARM390) is a close
SNC80 derivative [22], reported to be a poorly internalizing
agonist in a neuroblastoma cell line [23]. We compared ARM390
and SNC80 activities throughout this study. Met-enkephalin was
also examined ex vivo, as a prototypic endogenous delta opioid
receptor agonist.
We first characterized the pharmacological profiles of the three
delta receptor agonists in brain membranes prepared from DOR-
eGFP mice. In competition binding experiments, all three ligands
displaced [
3H]naltrindole with binding affinities in the nanomolar
range (Table 1). The two synthetic alkaloids, SNC80 and
ARM390, had affinities which were approximately 10 times
greater than the affinity of Met-enkephalin. We compared
functional responses of all three ligands in the [
35S]GTPcS
binding assay (Table 1). The three agonists had similar potencies.
Both SNC80 and ARM390 produced similar levels of receptor
stimulation, while Met-enkephalin was slightly more efficacious.
SNC80 and ARM390 therefore bind to and activate the DOR-
eGFP receptor with comparable potencies and efficacies.
SNC80 and ARM390 differentially internalize the DOR-
eGFP receptor in live neurons
Data mainly from transfected cellular models ([24], and
references therein), and also from in vivo experiments [12,25,26],
indicate that delta agonists trigger delta receptor internalization.
Similarly, our initial examination of primary neurons from DOR-
eGFP mice, showed that Met-enkephalin and SNC80 trigger rapid
internalization of the fluorescent receptor [13]. Here we compared
internalization evoked by Met-enkephalin, SNC80 and ARM390
in live hippocampal and striatal neurons from DOR-eGFP mice,
by real time confocal microscopy. Prior to drug administration,
DOR-eGFP fluorescence was distributed along the entire cell
membrane. At all tested concentrations (10 nM, 100 nM, 1 mM)
Met-enkephalin and SNC80, induced rapid DOR-eGFP cluster
formation and complete loss of surface labeling (see Figure 1A and
Movies S1 and S2). In addition, co-expression of these internalized
receptors with a lysosome marker (LysoTracker Red DND 99;
Figure 1B) indicated that DOR-eGFP receptors were targeted to
the lysosomal compartment. In contrast, 100 nM ARM390 failed
to induced receptor endocytosis (Figure 1A and Movie S3). A 100-
times higher ARM390 concentration was required to internalize
DOR-eGFP (Movie S4). Similar results were obtained for both
neuronal preparations (Table 1).
In conclusion, although SNC80 and ARM390 having similar
binding properties, the two drugs produce distinct internalization
efficacies at DOR-eGFP receptors. SNC80 is a high-internalizing
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agonist under ex vivo experimental conditions.
SNC80 and ARM390 differentially regulate DOR-eGFP
receptor function in vivo
We next determined whether equipotent (see Figure S1) doses of
SNC80 and ARM390 differentially affected behavior in a model
of inflammatory pain. DOR-eGFP mice were tested in the
Complete Freud’s Adjuvant (CFA) model of inflammatory pain
[27]. In this behavioral model, delta agonists show anti-allodynic
and anti-hyperalgesic properties [17–19] and delta receptor
knockout mice display enhanced pain [28]. CFA was injected
either in the paw or the tail of DOR-eGFP mice to measure
mechanical or thermal responses, respectively.
Forty-eight hours post-CFA, we observed mechanical allodynia
using von Frey stimulation (paw CFA) and heat hyperalgesia in a
tail immersion assay (tail CFA) (Figure 2B, C and D, dashed line
vs. control). CFA-evoked pain was almost completely abolished
with the first administration of either SNC80 or ARM390, and
both produced comparable effects (Figure 2B, C and D, Test 1).
However, a subsequent injection of SNC80 or ARM390 produced
distinct responses. The pain-relieving effects of SNC80 were
completely lost while ARM390 remained fully active (Figure 2B,
Test 2).
To determine if the acute behavioral desensitization after
SNC80 treatment could be generalized to other delta agonists, we
performed a cross-over experiment (Figure 2C). As before, the first
injection of SNC80 and ARM390 similarly reversed both CFA-
induced mechanical and thermal pain (Test 1). Mice treated with
SNC80 were subsequently administered ARM390, but this
injection was ineffective. Conversely animals treated with
ARM390 were re-challenged with SNC80, and this significantly
attenuated both mechanical and thermal pain responding
(Figure 2C, Test 2).
In order to address the possibility that these results were limited
to DOR-eGFP mice, we tested for acute behavioral desensitization
in commercial C57BL/6J mice (Figure 2D). The results were
similar to those obtained with DOR-eGFP mice. CFA in the paw
or tail produced robust allodynic or hyperalgesic responses, which
were completely reversed by the first injection of SNC80 or
ARM390 (Figure 2D, Test 1). As seen previously, a subsequent
injection of SNC80 was ineffective, but repeated injection of
ARM390 continued to attenuate mechanical allodynia and
thermal hyperalgesia (Figure 2D, Test 2).
Altogether, SNC80 treatment prevents further responding to
either agonist, whereas ARM390 treatment does not disrupt
subsequent responses to the two drugs. Therefore, initial exposure
to the high-internalizing but not the low-internalizing agonist
abolishes DOR function in vivo.
DOR-eGFP receptor internalization in vivo parallels
receptor phosphorylation and uncoupling from G
proteins
We characterized the status of DOR-eGFP receptors in
neurons, at the time of the second injection. Three other groups
of animals were treated identically to control, SNC80 and
ARM390 groups, but were sacrificed for ex vivo analysis, instead
of receiving the second drug treatment (see time line in Figure 2).
In the first group of animals we examined DOR-eGFP
subcellular localization in three CNS regions (striatum, hippo-
campus, and spinal cord) as well as in dorsal root ganglia using
confocal microscopy (Figure 3A). SNC80-treated animals showed
robust internalization of DOR-eGFP in all regions examined.
Table 1. Pharmacological and internalization properties of delta agonists at the DOR-eGFP receptor (see Materials and Methods).
Affinity (Competition Binding) G protein coupling ([
35S]GTPcS binding)
Ligand Ki (nM) EC50 (nM) Emax (% basal)
SNC80 9.160.5*** 121.5636.3 228.468.7
ARM390 2.360.3*** 169.369.5 214.369.6
Met-enkephalin 66.85612.9 94.5764.0 294.263.9
***
Endocytosis efficiencies
Concentration (nM) Striatum Hippocampus
E1/2 (min) E1/2 (min)
SNC80 1000 1.860.5 3.360.8
100 3.860.8 4.960.5
10 10.661.8 14.962.0
ARM390 1000 4.760.7 5.860.3
100 ND ND
Met-enkephalin 1000 1.3260.22 1.4160.37
100 3.9360.16 2.8760.52
10 7.1360.98 4.0660.75
For competition binding experiments, affinities are shown as Ki values. For the [
35S]GTPcS assay, ligand potencies are expressed as EC50 values, and maximum activation
levels are indicated as Emax. Basal binding (100%) is defined as [
35S]GTPcS responses in absence of ligand. All data are expressed as mean6SEM from 3–4 independent
experiments performed in duplicate with two different membrane preparations.
***p,0.001, one-way ANOVA. In primary neuron cultures, quantification of agonist-induced internalization was performed using real time confocal microscopy. The
number of DOR-eGFP vesicles at various time points was counted from the corresponding videos. When internalization occurred it was completed by 60 min, and
the number of DOR-eGFP vesicles at this time point was defined as 100%. Endocytosis efficiencies (E1/2) were defined as the time needed to internalize 50% of DOR-
eGFP. ND indicates that weak or no change in surface labeling was detected. Data are mean6SEM for 4–9 independent experiments.
doi:10.1371/journal.pone.0005425.t001
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eGFP was observed on the cell surface of neurons, in both cell
bodies and processes. In contrast, almost no DOR-eGFP vesicles
were observed in the ARM390 group, where continuous
fluorescent labeling was clearly located on the cell surface.
Quantification of intracellular fluorescence confirmed that
SNC80, but not ARM390, induced internalization (Figure 3A,
histogram). Noticeably, injections of higher doses of ARM390 (30
and 60 mg/kg) also failed to produce DOR-eGFP internalization
(data not shown), confirming the poor internalization potency of
this compound in vivo. Hence, although both agonists showed
similar pain relieving properties, only SNC80 produced DOR-
eGFP internalization in vivo in both central and peripheral nervous
systems.
In the second group of animals, we investigated DOR-eGFP
coupling to G proteins in brain membranes and spinal cord
homogenates at the time of the second injection (Figure 3B).
Concentration response curves in the [
35S]GTPcS binding assay
were established to both SNC80 and ARM390. SNC80-treated
animals showed a 50–70% decrease in Emax responses, indicative
Figure 1. Delta agonists differentially internalize DOR-eGFP in primary neurons. Striatal and hippocampal primary neurons were treated
for 60 minutes with Met-enkephalin, SNC80 or ARM390. (A) Representative images of hippocampal neurons treated with 100 nM of agonists are
shown. Scale bar is 12 mm. (B) Internalized DOR-eGFP co-localized with lysosomes. Striatal primary neurons were incubated with Met-enkephalin
(100 nM) or SNC80 (100 nM) for 20 or 120 minutes, along with LysoTracker Red DND 99 (300 nM); scale bar is 12 mm.
doi:10.1371/journal.pone.0005425.g001
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showed similar [
35S]GTPcS binding to the control group,
demonstrating that surface receptors remained functionally
coupled.
In the third group, we determined whether SNC80 and
ARM390 induce different DOR-eGFP phosphorylation states, as
GPCR desensitization is often preceded by agonist-induced
receptor phosphorylation [7,29]. DOR-eGFP mice were treated
with drug, and the presence of phospho-DOR Ser(363) was
determined using western blot (Figure 3C). Only SNC80
treatment produced significantly higher levels of phosphorylated
receptor as compared to controls. To control for the specificity of
the antibody, delta opioid receptor knockout mice were also
treated with SNC80 (10 mg/kg ), and in this case no phospho-
DOR band was detected. Thus, SNC80-induced phosphorylation
of DOR-eGFP likely contributes to receptor desensitization, a
phenomenon not observed after ARM390 treatment.
Hence, SNC80 triggered DOR-eGFP phosphorylation, uncou-
pling and endocytosis, while none of these events occurred with
ARM390. This result indicates that regulatory processes, which
occur at the neuronal level, are triggered by SNC80 only and are
likely associated in vivo.
Behavioral desensitization is transient
We finally determined whether SNC80-induced behavioral
desensitization could be reversed over time (Figure 4A). As seen
previously, first exposure to SNC80 significantly attenuated
allodynia, and a subsequent injection 4 hours later was ineffective.
In contrast, mice that were re-challenged 24 hours following the
first injection showed a clear anti-allodynic response to SNC80.
Correspondingly, robust DOR-eGFP endocytosis was observed 4,
but not 24 hours following drug treatment (Figure 4B). Hence,
SNC80-induced internalization and the concomitant behavioral
desensitization are transient phenomena.
Discussion
Delta opioid receptors undergo long-term sequestration
in vivo
GPCR trafficking to and from the cell surface has been
extensively studied in cellular models [2]. Agonist-induced
endocytosis reduces the number of receptors accessible to
extracellular agonists, and decreases drug efficacy shortly after
internalization. Subsequently, internalized GPCRs can be sorted
into multiple regulatory pathways. Some receptors recycle rapidly
from early endosomes, leading to prompt resensitization of
receptor function. Other receptors are targeted to late endosomes
and may recycle slowly or be targeted for lysosomal degradation,
resulting in prolonged attenuation of agonist-induced responses
(for review see [2,5]).
Many studies in neuronal and non-neuronal cell lines indicate
that delta receptors are degraded after agonist-induced internal-
ization [30–33]. However, no study has addressed the trafficking
of delta receptors in vivo. Our data indicate that receptor
internalization does not result in fast receptor recycling in DOR-
eGFP mice. Four hours after the first injection of SNC80, a
substantial amount of DOR-eGFP remained in intracellular
clusters, and surface fluorescence was undetectable in neurons
Figure 2. Differential in vivo regulation of DOR by SNC80 and
ARM390. (A) Time line of the experiments is shown on top. (B, C and
D) Test 1: mechanical (CFA paw) and thermal (CFA tail) responses in
animals treated with vehicle (Control), SNC80 (10 mg/kg) or ARM390
(10 mg/kg). Test 2: animals re-challenged four hours later with the same
drug (B and D) or the other drug (C). Dashed lines represent baseline
mechanical or thermal responses pre-CFA. For drug effects *** p,0.001,
two-way RM ANOVA, n=5–8 mice/group.
doi:10.1371/journal.pone.0005425.g002
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PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5425Figure 4. Restoration of DOR-eGFP function. (A)Test 1: mechanical (CFA paw) and thermal (CFA tail) responses in animals treated with vehicle
(Control) or SNC80 (10 mg/kg). Test 2: animals re-challenged 4 (left panels) or 24 hours (right panels) with SNC80. Dashed lines represent baseline
mechanical or thermal responses pre-CFA. For drug effects * p,0.05, **p,0.01, two-way RM ANOVA, n=4–8 mice/group. (B) CNS regions were
analyzed by confocal microscopy, and representative images are shown. Mean intracellular DOR-eGFP fluorescence was quantified in 5–7 sections/
region/mouse. White bars, control group; black bars, SNC80 group re-challenged 4 hours after Test 1; grey bars, SNC80 group re-challenged 24 hours
after Test 1; **p,0.01, *** p,0.001, one-way ANOVA, n=3–5 mice/group.
doi:10.1371/journal.pone.0005425.g004
Figure 3. SNC80, but not ARM390, triggers DOR-eGFP internalization, uncoupling, and phosphorylation in vivo. Separate groups of
DOR-eGFP mice were treated as in Figure 2, but instead of the second drug administration (A and B) or 20 min later (C) tissue was harvested for ex
vivo analysis. (A) CNS regions and dorsal root ganglia were analyzed by confocal microscopy and representative images are shown. Mean intracellular
DOR-eGFP fluorescence was quantified in 5–7 sections/region/mouse. White bars, control group; black bars, SNC80 group; grey bars, ARM390 group;
*p,0.05, **p,0.01, *** p,0.001, one-way ANOVA, n=3–5 mice/group. (B) [
35S]GTPcS concentration-response curves to SNC80 and ARM390. y-axis
shows mean6SEM specific [
35S]GTPcS binding expressed as percentage basal binding (i.e. absence of agonist). Experiments were performed in
triplicate; n=3–5 mice/group. (C) Western blot of phospho-DOR (Ser 363) in hippocampal samples collected 20 min post-drug injection. KO, DOR
knockout mouse challenged with SNC80 (10 mg/kg). Mean optical density was assessed for n=3 mice/group.
doi:10.1371/journal.pone.0005425.g003
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some recycling of DOR-eGFP occurred after SNC80 treatment,
which was not detectable in our experimental conditions.
However, our behavioral data indicate that at this time point
there was not enough DOR-eGFP on the cell surface to respond to
the second infusion of agonist. Therefore, the predominant effect
of agonist-induced internalization was long-term sequestration.
Furthermore, in primary neurons from DOR-eGFP mice treated
with SNC80 or Met-enkephalin, we found that internalized DOR-
eGFP colocalized with a lysosomal marker as soon as two hours
after agonist exposure. These data strongly suggest that internal-
ized delta opioid receptors are targeted for degradation in living
neurons. Together, our ex vivo and in vivo data definitively classify
delta receptors among slow-recycling/degrading GPCRs. It
remains to be determined if the restored pool of functional
DOR-eGFP receptors observed at the surface of neurons 24 hours
after agonist treatment arises from slow externalization of internal
receptor pools or receptor neosynthesis.
Distinct ligand-dependent conformational states control
DOR-eGFP activity in vivo
The results of this study indicate that DOR-eGFP internaliza-
tion was strongly correlated to receptor phosphorylation and
uncoupling from G proteins. SNC80 produced robust DOR-eGFP
endocytosis, which was concomitant with an increase in receptor
phosphorylation and a decrease in [
35S]GTPcS binding. ARM390
did not produce internalization, and correspondingly there was no
change in [
35S]GTPcS responses. Thus, in our experiments
receptor coupling and internalization either occurred together or
not at all. Evidence from previous in vitro studies suggest that
GPCR uncoupling can occur without internalization. In neuro-
blastoma cells, ARM390 incubation resulted in desensitization of
the cAMP response, but no change in receptor internalization
[23]. In the same cell line, pharmacological treatments that block
receptor internalization, such as concanavalin A and hypertonic
sucrose, did not affect receptor desensitization [34]. In this study,
we observed no dissociation between these two events in vivo,
suggesting that in this case in vitro observations may not always
predict in vivo processes.
One may speculate on molecular mechanisms governing the in
vivo phosphorylation-uncoupling-internalization regulatory re-
sponse that we observed. Studies in transfected systems have
proposed a general scheme for the desensitization of GPCR
signaling. The agonist-activated receptor is initially phosphorylat-
ed by GPCR kinases (GRKs), and the phosphorylated receptor, in
turn, recruits b-arrestin to the cell surface [6]. Arrestins promote
receptor internalization, and also physically prevent further
receptor coupling to G proteins (for review see [2,29]).
Considering this scenario, we observed that SNC80 but not
ARM390 produced DOR-eGFP phosphorylation on the Ser363
site. This site is a primary phosphorylation site following delta
agonist stimulation, and plays a significant role in subsequent delta
receptor desensitization and internalization [35,36]. The differ-
ence in the ability of SNC80 and ARM390 to produce
phosphorylation at this site, likely accounts for the divergent
internalization profiles of these two drugs. Further, a recent study
in transfected cells showed that delta receptors can adopt several
ligand-specific conformations, which produce different G protein
signaling complexes [37]. In our study, both SNC80 and ARM390
clearly activate a signaling cascade that leads to pain inhibition.
However, ARM390 may bind in a mode that produces receptor
signaling, but may not cause subsequent receptor phosphorylation
and internalization. In contrast, SNC80 may interact differentially
with the receptor binding pocket to promote a distinct active
conformation, which in turn triggers signaling, as well as receptor
phosphorylation and internalization. Consistent with this hypoth-
esis of two different receptor-agonist complexes, molecular models
that compared the two ligands indicated that both compounds
bound to the same region of the delta receptor, but that ARM390
only partially covered the conformational space occupied by
SNC80 [22].
A therapeutic potential for non-internalizing delta
agonists?
In this study we extensively characterized the in vitro and in vivo
properties of ARM390. This compound is a derivative of
SNC80, and has a higher selectivity for delta over mu and
kappa opioid receptors [22]. In DOR-eGFP brain membranes,
ARM390 acted as an agonist and had binding affinities and
potencies similar to SNC80, consistent with the initial charac-
terization of the compound in transfected cells [22]. Further,
ARM390 did not produce substantial receptor internalization
in vivo, as previously observed in cell lines [23]. The lack of
ARM390-induced internalization correlated with continued
receptor coupling to G proteins and in vivo efficacy of
ARM390 at the second drug administration. The inability of
ARM390 to induce receptor endocytosis, therefore, maintained
full receptor function across two sequential drug treatments.
From a therapeutic perspective, these properties could be
advantageous for chronic treatments. Previous studies have
shown the development of rapid tolerance to some of the
behavioral effects of SNC80 in rats [38]. Further, tolerance to
the effects of SNC80 on food response rates was also observed in
rhesus monkeys following both acute and chronic exposure to the
drug [39]. A non-internalizing delta agonist may induce less
analgesic tolerance, although this remains to be studied in
chronic treatment paradigms.
More generally, molecular mechanisms underlying tolerance
are likely unique to each GPCR-agonist combination. To date
the relationship between receptor internalization and in vivo
tolerance has largely been debated in the context of the mu
opioid receptor, where morphine tolerance represents a major
clinical limitation (see [40]). A classical view is that mu receptor
internalization strongly contributes to tolerance, supported
notably by the absence of tolerance to analgesic effects of
morphine in b-arrestin 2 knockout animals [41]. The observa-
tions that morphine poorly internalizes mu receptors [9,10,42],
and that sequestered mu receptors resensitize rapidly by
recycling ([40] and references therein), has led to a different
theory of opioid tolerance. Potent internalizing mu agonists
would allow continuous interruption and subsequent restoration
of receptor function, whereas morphine would produce accele-
rated in vivo tolerance via adaptive cellular responses to
uninterrupted signaling [43,44]. However, mechanistic hypoth-
eses from mu receptor data remain speculative, and are not
directly transposable to delta receptors where rapid recycling
does not occur.
In conclusion, we establish for the first time a direct link
between the localization and function of the delta opioid receptor
in vivo. Delta agonists reduce inflammatory pain, and the lack of
receptor internalization maintains the response whereas receptor
endocytosis acutely desensitizes this response. Our approach may
be valuably extended to other slow-recycling GPCRs, and increase
our knowledge of regulatory mechanisms driving in vivo GPCR
function. The application of these findings may also have
important consequences for drug discovery in many therapeutic
areas.
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DOR-eGFP mice
All experiments were performed in accordance with the
European Communities Council Directive of 24 November
1986. Knock-in mice were produced by homologous recombina-
tion. In these mice the eGFP cDNA was introduced into exon 3 of
the delta opioid receptor gene, in frame and 59 from the stop
codon [13]. Receptor binding and signaling properties were
unchanged in DOR-eGFP mutants. Mice aged 12 weeks on
average, were housed in a temperature- and humidity-controlled
animal colony on a 12 h dark-light cycle. Food and water were
available ad libitum.
Delta agonists
SNC80 [21] is a widely used non-peptidic compound that shows
high delta selectivity in vivo, and was selected as a reference delta
agonist in this study (Tocris). AR-M100390 (ARM390, N,
N-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide) is a
SNC80 derivative [22], reported to be a poorly internalizing
agonist in a neuroblastoma cell line [23] and was synthesized at
AstraZeneca R&D Montreal (Canada). ARM390 was adminis-
tered per os (p.o) by gavage, as it is an irritant when injected i.p.
(AstraZeneca personal communication).
Ex vivo tissue analysis of DOR-eGFP mice
Membrane preparations were carried out as described previ-
ously [45]. Whole brain and the lumbar segment of the spinal cord
were removed, immediately frozen in isopentane or dry ice, and
stored at 280uC prior to use. For the brain, [
3H]naltrindole and
[
35S]GTPcS assays were performed on whole brain membranes.
The [
35S]GTPcS assay for the spinal cord was performed on
homogenates. Whole brain membranes were prepared by
homogenizing the brain in ice-cold 0.25 M sucrose solution 10
vol (ml/g wet weight of tissue). Samples were then centrifuged at
1100 g for 10 min. Supernatants were collected and diluted 5
times in buffer containing 50 mM TrisHCl (pH 7.4) and 1 mM
EDTA, following which they were centrifuged at 35 000 g for
30 min. The pellets were homogenized in 2 ml ice-cold sucrose
solution (0.32 M), aliquoted and kept at 280uC until further use.
Spinal cords were prepared for binding by homogenization in the
binding buffer (50 mM TrisHCl, 3 mM MgCl2, 0.2 mM EGTA,
100 mM NaCl, pH7.4) and used immediately.
For competition studies, 50 mg of membrane proteins were
incubated with 1 nM [
3H]naltrindole, in the presence of variable
concentrations (10
24 to 10
212 M) of SNC80 or ARM390 for 1 h
at 25uC. Membranes were washed and filtered, and radioactivity
was quantified using a liquid scintillation counter. Assays were
performed in duplicates, in 3 to 4 experiments using 2 different
membrane preparations.
For each [
35S]GTPcS binding assay 5 mg of protein was used
per well. Samples were incubated with and without delta opioid
receptor agonists (10
24 to 10
212 M), for 1 hour at 25uC in assay
buffer containing 30 mM GDP and 0.1 nM [
35S]GTPcS. For
whole brain membranes, the buffer used was 50 mM TrisHCl
(pH 7.4), 3 mM MgCl2, 100 mM NaCl, 0.2 mM EGTA. In the
case of spinal cord homogenates, the buffer was the same as that
used for homogenization. For saturation experiments, incubation
was terminated by rapid filtration and washing in ice-cold buffer
(50 mM TrisHCl, 5 mM MgCl2, 50 mM NaCl, pH 7.4). Bound
radioactivity was quantified using a liquid scintillation counter.
Non-specific binding was defined as binding in the presence of
10 mM GTPcS, and basal binding indicates binding in the absence
of agonist.
For Western blot analysis of phosph-DOR, DOR-eGFP mice
were administered either DOR agonist (10 mg/kg) or vehicle and
sacrificed 20 min later. Immediately after decapitation, the
hippocampus was rapidly dissected and kept at 280uC. Frozen
hippocampi were homogenized and sonicated in 2% SDS buffer
containing (in mM) 50 Tris, pH 6.8, 1 EDTA, 1 sodium fluoride,
and 1 sodium orthovanadate, as well as a Complete protease
inhibitor mixture (Roche Applied Science). Homogenates were
boiled at 96u for 4 min, and total protein content was determined
by Bradford assay. Twenty micrograms of protein was loaded on a
SDS-10% bisacrylamide gel and separated by constant voltage of
100 V for 1.5 h, then transferred to polyvinylidene difluoride
membranes at a constant voltage of 100 V for 1 h in cold transfer
buffer (Tris-borate). Membranes were blocked in 5% nonfat dry
milk in a phosphate buffered saline (PBS) solution containing 0.2%
Tween 20, for 2 h. Membranes were probed for phospho-DOR
with primary anti-phospho-DOR (Ser363) antibody (rabbit
polyclonal antibody, 1:1000 Cell Signaling Technology) diluted
in 5% bovine serum albumin and incubated overnight at 4uC.
Membranes were washed three times for 10 min in PBS-0.2%
Tween solution and incubated for 1 h at room temperature in
horseradish peroxidase conjugated anti-rabbit IgG secondary
antibodies (1:20,000; GE Healthcare). The signal was developed
using enhanced chemiluminescent reagents (ECL+; GE Health-
care) and quantified using IMAGEJ. As a loading control, b-
tubulin content was analyzed on the same membrane. Membranes
were stripped of antibodies for 30 min (Re-blot plus solution;
Millipore), rinsed, and blocked at room temperature for 2 h. Blots
were reincubated with b-tubulin primary antibody (mouse
monoclonal) at room temperature for 3 hours, then washed three
times for 10 min and incubated for 1 h at room temperature in
horseradish-peroxidase conjugated anti-mouse IgG secondary
antibodies (1:20,000; GE Healthcare) before reaction with ECL+
solution.
To determine the subcellular distribution of DOR-eGFP after
agonist stimulation, mice were anaesthetized with ketamine/
xylazine (100/10 mg/kg) and intracardially perfused with 10 ml
9.25% sucrose in ddH2O followed by 30 ml 4% paraformalde-
hyde in 0.1 M phosphate buffer (PB; pH 7.4). Brains, spinal cords
and dorsal root ganglia were then post-fixed for 2 hours at 4uCi n
the fixative solution. The tissue was then cryoprotected at 4uCi na
30% sucrose, 0.1 M PB solution until the tissue sank. Tissue was
then frozen in isopentane and stored at 280uC until cut. Freely
floating sections were cut at 30 mM in a cryostat. Sections were
mounted on Superfrost
TM glass slides in 0.01 M PBS, and DOR-
eGFP receptor distribution was immediately examined in five
different delta receptor-rich regions. All samples were observed
under Leica confocal microscopes (SP1 or SP2UV; 636objective
and numerical aperture of 1.32), and the LCS (Leica) software was
used for image acquisition. Quantification of cytoplasmic mean
fluorescence intensity was determined using IMAGEJ software.
Nuclear fluorescence defined the background level and was
subtracted from the intracellular fluorescence measures. For each
region several intracellular samples were taken and averaged to
determine the intracellular mean fluorescence. In total, 5–7
different neurons were examined/region/mouse; n=3–5 mice/
group.
Internalization in primary neuron cultures from DOR-
eGFP mice
Both the preparation of primary neuron cultures, and the real
time confocal microscopy were performed as described previously
[13]. Briefly, P0 mice pups were decapitated, and hippocampi
and striata were dissected and digested with papain (15 U/ml,
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glass-bottom dishes coated with poly-L-lysine (PLL, Sigma) in
B27/NeurobasalA medium (Invitrogen) completed with 0.5 mM
glutamine and antibiotics. Cells were plated at a density of
8610
4 cells/cm
2. Medium was replaced 30 min after plating,
and half the medium changed every 5–7 days. Cultures were
maintained for 15 days in vitro (DIV). Fully matured primary
neurons (DIV 10 to 14) were used for agonist-induced receptor
internalization studies. Samples were observed under a Leica
confocal microscope (SP2 AOBS MP) using a heated stage
(Tempcontrol 37-2, Pecon) and 636 objective (zoom 46)a t
37uC. Images were recorded over 60 minutes, and reconstituted
videos (TIMT; in-house software) contained 86 images and lasted
3 seconds. Primary neuron cultures were acutely treated with
SNC80 (10 nM, 100 nM, 1 mM), or ARM390 (100 nM, 1 mM,
10 mM). When internalization occurred, it was completed by
60 min and the number of vesicles was counted manually at 30
to 46 different time points in images extracted from recorded
videos. The number of DOR-eGFP vesicles at 60 min was
defined as 100%. Altogether, 4 to 9 independent experiments
were performed/agonist/concentration.
Inflammatory pain in DOR-eGFP mice
All experiments were performed between 8:00–16:00 h. In all
cases DOR-eGFP animals were habituated to the testing area for
20 minutes daily for 2 days prior to baseline testing. Two different
variations of the Complete Freund’s Adjuvant (CFA) model of
inflammatory pain were used. To assess mechanical pain CFA was
injected into the paw. To assess thermal pain CFA was injected
into the tail. Separate groups of animals were used for each
endpoint.
For mechanical responses, the threshold for responses to
punctate mechanical stimuli (mechanical allodynia) was tested
according to the up-and-down method [46]. In this case, the
plantar surface of the animal hindpaw was stimulated with a series
of eight von Frey filaments (bending force ranging from 0.01 to
2 g). Prior to the injection of CFA baseline mechanical responses
(dashed line) were determined. Inflammation was induced by
injecting 8 ml of CFA into the plantar surface of the paw, and
animals were subsequently tested 48 hours later [27].
For thermal responses, heat hyperalgesia was assessed by
immersing the tail (5 cm from the tip) into a 46uC water bath.
Tail withdrawal latencies were determined, and a cut-off of 40 s
was established. Prior to the injection of CFA baseline mechanical
responses (dashed line) were determined. Inflammation was
induced by injecting 20 ml of CFA 3 cm from the tip of the tail,
and all drug tests occurred 48 hours later.
In order to ensure that all animals were treated similarly, each
mouse received both i.p. and p.o. injections. Therefore, animals
challenged with SNC80 (10 mg/kg, i.p.) also received a p.o.
injection of dH2O (SNC80 group), those challenged with
ARM390 (10 mg/kg, p.o.) received an i.p. injection of 0.9%
saline (ARM390 group), and control animals were injected with
i.p. saline and p.o. dH2O (Control group). Pain responses were
assessed 45 minutes after drug treatment (Test 1). Mice were then
re-challenged with drug or vehicle treatments 4 h or 24 h after the
first test, and tested again 45 min later (Test 2).
Statistical Analysis
All non-linear regression analysis was performed with Graph-
Pad Prism v4 (GraphPad San Diego, CA). In vitro pharmacology
experiments were analyzed using a one-way ANOVA. For
behavioral experiments, a two-way repeated measures ANOVA
was performed using Sigmastat software. Multiple comparisons
were made using Bonferroni corrected t-tests. For quantification of
intracellular fluorescence, a one-way ANOVA was performed, and
Tukey’s tests were used for post-hoc analysis.
Supporting Information
Figure S1 SNC80 and ARM390 produce comparable pain-
relieving effects. DOR-eGFP mice were tested 48 h after
intraplantar injection of CFA into the paw. Separate groups of
mice were challenged with differing doses of SNC80 or ARM390,
and mechanical allodynia was assessed 45 min post-drug. Dashed
line represents basal mechanical responses pre-CFA. *** p,0.001,
two-way ANOVA, n=3–4 mice/group.
Found at: doi:10.1371/journal.pone.0005425.s001 (0.74 MB TIF)
Movie S1 Real time confocal imaging of Met-enkephalin
(100 nM) induced DOR-eGFP internalization in a primary
hippocampal neuron. A representative movie is shown (n=4).
Agonist was added at time 0, and remained in the bath for the full
recording duration. Images were automatically recorded during
60 minutes, with increasing time intervals. For details see Methods
section.
Found at: doi:10.1371/journal.pone.0005425.s002 (1.83 MB
MPG)
Movie S2 Real time confocal imaging of SNC80 (100 nM)
induced DOR-eGFP internalization in a primary hippocampal
neuron. A representative movie is shown (n=5). Agonist was
added at time 0, and remained in the bath for the full recording
duration. Images were automatically recorded during 60 minutes,
with increasing time intervals. For details see Methods section.
Found at: doi:10.1371/journal.pone.0005425.s003 (2.55 MB
MPG)
Movie S3 Real time confocal imaging of ARM390 (100 nM),
which failed to induce DOR-eGFP internalization in a primary
hippocampal neuron. A representative movie is shown (n=6).
Agonist was added at time 0, and remained in the bath for the full
recording duration. Images were automatically recorded during
60 minutes, with increasing time intervals. For details see Methods
section.
Found at: doi:10.1371/journal.pone.0005425.s004 (3.12 MB
MPG)
Movie S4 Real time confocal imaging of ARM390 (1 mM)
induced DOR-eGFP internalization in a primary hippocampal
neuron. A representative movie is shown (n=4). Agonist was
added at time 0, and remained in the bath for the full recording
duration. Images were automatically recorded during 60 minutes,
with increasing time intervals. For details see Methods section.
Found at: doi:10.1371/journal.pone.0005425.s005 (2.18 MB
MPG)
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